Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia

Hepatology. 2013 Jul;58(1):442-5. doi: 10.1002/hep.26472. Epub 2013 May 31.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Arteriovenous Malformations / etiology*
  • Cardiac Output / drug effects*
  • Female
  • Humans
  • Liver / blood supply*
  • Male
  • Telangiectasia, Hereditary Hemorrhagic / drug therapy*
  • Telangiectasia, Hereditary Hemorrhagic / physiopathology*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized